Illumina gets funds for bead-based proteomic arrays:
This article was originally published in Clinica
Illumina has received a $1.2m grant from the US National Institutes of Health to continue its development of high-multiplex, low-cost arrays to profile protein activity in small volumes of cells or biological fluids. Identifying protein profiles will be valuable in a range of markets including diagnostics, said the San Diego, California firm. By profiling and understanding protein activity, pharmaceutical and biotech firms can identify more targeted drug compounds and discover relevant biomarkers for use in diagnostic products. The company added that its proprietary BeadArray technology provided the throughput, cost-effectiveness and flexibility needed to enable researchers to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics.